Apple's Record Q1: Can It Last Amid Supply Chain Woes?
Apple delivered record-breaking Q1 results with $143.8B revenue and 38% China growth, but memory shortages and supply constraints threaten future margins.
NOTRELOAD AI
Jefferies Starts Coverage on Definium Therapeutics with Buy Rating and $30 Target
Jefferies initiated coverage on Definium Therapeutics with a Buy rating, citing strong Phase IIb results for its anxiety drug DT120 and high confidence ahead of Phase III trials.
Quince Therapeutics Halts A-T Drug Development After Phase 3 Trial Miss
Quince Therapeutics ends eDSP development for ataxia-telangiectasia after Phase 3 NEAT trial fails primary endpoints. Stock plunges 91% as company explores strategic options.
Elon Musk Eyes Empire Consolidation: SpaceX Explores Mergers with Tesla and xAI
SpaceX is weighing potential mergers with both Tesla and xAI as Elon Musk considers consolidating his business empire ahead of a blockbuster IPO potentially valuing SpaceX at $1.5 trillion.
Fractyl's Weight Maintenance Study Shows Modest Results After GLP-1 Stoppage
Fractyl Health's (GUTS) REMAIN-1 study reveals limited weight maintenance benefits with Revita procedure after stopping GLP-1 medications, raising questions about effectiveness.
JPMorgan and BTIG Stand by Carvana After Gotham City Short Report
JPMorgan and BTIG maintain positive ratings on Carvana, disputing Gotham City Research’s short-seller claims and highlighting misrepresented data.